212 related articles for article (PubMed ID: 29712773)
21. B cell receptors in TCL1 transgenic mice resemble those of aggressive, treatment-resistant human chronic lymphocytic leukemia.
Yan XJ; Albesiano E; Zanesi N; Yancopoulos S; Sawyer A; Romano E; Petlickovski A; Efremov DG; Croce CM; Chiorazzi N
Proc Natl Acad Sci U S A; 2006 Aug; 103(31):11713-8. PubMed ID: 16864779
[TBL] [Abstract][Full Text] [Related]
22. ROR1 can interact with TCL1 and enhance leukemogenesis in Eμ-TCL1 transgenic mice.
Widhopf GF; Cui B; Ghia EM; Chen L; Messer K; Shen Z; Briggs SP; Croce CM; Kipps TJ
Proc Natl Acad Sci U S A; 2014 Jan; 111(2):793-8. PubMed ID: 24379361
[TBL] [Abstract][Full Text] [Related]
23. B-cell antigen receptor expression and phosphatidylinositol 3-kinase signaling regulate genesis and maintenance of mouse chronic lymphocytic leukemia.
Schmid VK; Khadour A; Ahmed N; Brandl C; Nitschke L; Rajewsky K; Jumaa H; Hobeika E
Haematologica; 2022 Aug; 107(8):1796-1814. PubMed ID: 35021605
[TBL] [Abstract][Full Text] [Related]
24. Development of CLL in the TCL1 transgenic mouse model is associated with severe skewing of the T-cell compartment homologous to human CLL.
Hofbauer JP; Heyder C; Denk U; Kocher T; Holler C; Trapin D; Asslaber D; Tinhofer I; Greil R; Egle A
Leukemia; 2011 Sep; 25(9):1452-8. PubMed ID: 21606964
[TBL] [Abstract][Full Text] [Related]
25. Chronic lymphocytic leukemia cells in a lymph node microenvironment depict molecular signature associated with an aggressive disease.
Mittal AK; Chaturvedi NK; Rai KJ; Gilling-Cutucache CE; Nordgren TM; Moragues M; Lu R; Opavsky R; Bociek GR; Weisenburger DD; Iqbal J; Joshi SS
Mol Med; 2014 Jul; 20(1):290-301. PubMed ID: 24800836
[TBL] [Abstract][Full Text] [Related]
26. High TCL1 levels are a marker of B-cell receptor pathway responsiveness and adverse outcome in chronic lymphocytic leukemia.
Herling M; Patel KA; Weit N; Lilienthal N; Hallek M; Keating MJ; Jones D
Blood; 2009 Nov; 114(21):4675-86. PubMed ID: 19770358
[TBL] [Abstract][Full Text] [Related]
27. CD74 is dispensable for development of chronic lymphocytic leukemia in
Barthel R; Fedorchenko O; Velmans T; Rosen N; Nguyen PH; Reinart N; Florin A; Herling M; Hallek M; Fingerle-Rowson G
Leuk Lymphoma; 2020 Dec; 61(12):2799-2810. PubMed ID: 32667245
[TBL] [Abstract][Full Text] [Related]
28. Evidence for Non-Cancer-Specific T Cell Exhaustion in the Tcl1 Mouse Model for Chronic Lymphocytic Leukemia.
Parigger T; Gassner FJ; Scherhäufl C; Bakar AA; Höpner JP; Hödlmoser A; Steiner M; Catakovic K; Geisberger R; Greil R; Zaborsky N
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34206229
[TBL] [Abstract][Full Text] [Related]
29. Chronic lymphocytic leukemia disease progression is accelerated by APRIL-TACI interaction in the TCL1 transgenic mouse model.
Lascano V; Guadagnoli M; Schot JG; Luijks DM; Guikema JE; Cameron K; Hahne M; Pals S; Slinger E; Kipps TJ; van Oers MH; Eldering E; Medema JP; Kater AP
Blood; 2013 Dec; 122(24):3960-3. PubMed ID: 24100449
[TBL] [Abstract][Full Text] [Related]
30. T Cell Leukemia/Lymphoma 1A is essential for mouse epidermal keratinocytes proliferation promoted by insulin-like growth factor 1.
Bresin A; Ragone G; Cristofoletti C; Arcelli D; Bassi C; Caprini E; Fiorenza MT; Helmer Citterich M; Russo G; Narducci MG
PLoS One; 2018; 13(10):e0204775. PubMed ID: 30286151
[TBL] [Abstract][Full Text] [Related]
31. Role of the splenic microenvironment in chronic lymphocytic leukemia development in Eµ-TCL1 transgenic mice.
Collard JP; McKenna MK; Noothi SK; Alhakeem SS; Rivas JR; Rangnekar VM; Muthusamy N; Bondada S
Leuk Lymphoma; 2022 Aug; 63(8):1810-1822. PubMed ID: 35258388
[TBL] [Abstract][Full Text] [Related]
32. Expanded antigen-experienced CD160
Bozorgmehr N; Okoye I; Oyegbami O; Xu L; Fontaine A; Cox-Kennett N; Larratt LM; Hnatiuk M; Fagarasanu A; Brandwein J; Peters AC; Elahi S
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33931471
[TBL] [Abstract][Full Text] [Related]
33. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug.
Ramsay AG; Johnson AJ; Lee AM; Gorgün G; Le Dieu R; Blum W; Byrd JC; Gribben JG
J Clin Invest; 2008 Jul; 118(7):2427-37. PubMed ID: 18551193
[TBL] [Abstract][Full Text] [Related]
34. CD5+CD23+ leukemic cell populations in TCL1 transgenic mice show significantly increased proliferation and Akt phosphorylation.
Efanov A; Zanesi N; Nazaryan N; Santanam U; Palamarchuk A; Croce CM; Pekarsky Y
Leukemia; 2010 May; 24(5):970-5. PubMed ID: 20357824
[TBL] [Abstract][Full Text] [Related]
35. EOMES is essential for antitumor activity of CD8
Llaó-Cid L; Roessner PM; Chapaprieta V; Öztürk S; Roider T; Bordas M; Izcue A; Colomer D; Dietrich S; Stilgenbauer S; Hanna B; Martín-Subero JI; Seiffert M
Leukemia; 2021 Nov; 35(11):3152-3162. PubMed ID: 33731848
[TBL] [Abstract][Full Text] [Related]
36. PI3Kδ inhibition modulates regulatory and effector T-cell differentiation and function in chronic lymphocytic leukemia.
Hanna BS; Roessner PM; Scheffold A; Jebaraj BMC; Demerdash Y; Öztürk S; Lichter P; Stilgenbauer S; Seiffert M
Leukemia; 2019 Jun; 33(6):1427-1438. PubMed ID: 30573773
[TBL] [Abstract][Full Text] [Related]
37. Characterization of interleukin-10 receptor expression on B-cell chronic lymphocytic leukemia cells.
Jurlander J; Lai CF; Tan J; Chou CC; Geisler CH; Schriber J; Blumenson LE; Narula SK; Baumann H; Caligiuri MA
Blood; 1997 Jun; 89(11):4146-52. PubMed ID: 9166857
[TBL] [Abstract][Full Text] [Related]
38. The inhibitory receptor Siglec-G controls the severity of chronic lymphocytic leukemia.
Röder B; Fahnenstiel H; Schäfer S; Budeus B; Dampmann M; Eichhorn M; Angermüller S; Brost C; Winkler TH; Seifert M; Nitschke L
EMBO Rep; 2023 Aug; 24(8):e56420. PubMed ID: 37424400
[TBL] [Abstract][Full Text] [Related]
39. Chronic lymphocytic leukemia of Emu-TCL1 transgenic mice undergoes rapid cell turnover that can be offset by extrinsic CD257 to accelerate disease progression.
Enzler T; Kater AP; Zhang W; Widhopf GF; Chuang HY; Lee J; Avery E; Croce CM; Karin M; Kipps TJ
Blood; 2009 Nov; 114(20):4469-76. PubMed ID: 19755673
[TBL] [Abstract][Full Text] [Related]
40. PKCbeta is essential for the development of chronic lymphocytic leukemia in the TCL1 transgenic mouse model: validation of PKCbeta as a therapeutic target in chronic lymphocytic leukemia.
Holler C; Piñón JD; Denk U; Heyder C; Hofbauer S; Greil R; Egle A
Blood; 2009 Mar; 113(12):2791-4. PubMed ID: 19168795
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]